10-Q: Cooper Companies Swings to Q2 Loss on Litigation Charge

The Cooper Companies reported an 8% revenue increase to $1.08 billion but swung to a net loss due to a $271.6 million litigation accrual related to a surgical product recall.

Summary

• Net sales for the second quarter of fiscal 2026 increased 8% year-over-year to $1,081.5 million.
• The company reported a net loss of $77.9 million, or $0.40 per diluted share, compared to a net income of $87.7 million in the prior year quarter.
• A massive $271.6 million net litigation charge was recorded within selling, general, and administrative expenses related to the LifeGlobal embryo culture media recall.
• CooperVision net sales rose 8% to $723.5 million, driven by strong performance in silicone hydrogel lenses and myopia management products.
• CooperSurgical net sales increased 8% to $358.0 million, though the segment reported an operating loss of $225.0 million due to the litigation accrual.
• Total debt stood at $2,460.2 million as of April 30, 2026, with $1,383.0 million remaining available under the revolving credit facility.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed-to-negative report; while core revenue growth and CooperVision's performance are strong, the massive litigation liability and ongoing tax risks create significant near-term uncertainty for shareholders.

Positives

• Consolidated net sales grew 8% to $1,081.5 million, showing resilient demand across both business segments.
• CooperVision operating income increased 16% to $215.6 million, with operating margins improving to 30%.
• Toric and multifocal lens sales grew 11% to $364.9 million, led by Biofinity and MyDay franchises.
• Interest expense decreased 14% to $20.9 million due to lower interest rates and average debt balances.
• The company successfully extended the maturity of $950 million in term loans to February 2031.

Negatives

• Reported a quarterly net loss of $77.9 million, a significant reversal from the $87.7 million profit in Q2 2025.
• Operating income plummeted from a $184.8 million profit to a $31.0 million loss.
• CooperSurgical segment experienced a massive operating loss of $225.0 million.
• Asia Pacific sales for CooperVision declined 6% due to market softness in Japan.
• Working capital decreased significantly to $495.1 million from $993.6 million at the end of fiscal 2025.

Risks

• Product liability litigation related to the LifeGlobal embryo culture media recall involves over 140 lawsuits and 1,500 claimants.
• An ongoing dispute with UK HMRC regarding payroll tax from a 2014 acquisition carries a potential loss of up to £71.7 million plus interest.
• Exposure to foreign currency exchange rate fluctuations, particularly the British pound, Euro, and Japanese yen.
• Dependence on variable rate indebtedness which remains subject to interest rate risk.
• Potential for further litigation costs or settlements exceeding current insurance coverage and accruals.

Future Outlook

Management remains optimistic about long-term prospects for the worldwide contact lens and general healthcare markets. They expect continued demand for single-use silicone hydrogel products and myopia management solutions. However, they acknowledge significant uncertainties regarding global economic conditions, regulatory developments, and the ultimate resolution of ongoing litigation and tax disputes.

Management Comments

• Management concluded that a loss was probable and reasonably estimable regarding the LifeGlobal recall, particularly for exposure exceeding insurance coverage.
• The company believes the UK First-tier Tribunal's decision regarding the Sauflon tax dispute was incorrect and is in the process of appealing.
• Management continues to focus on greater worldwide market penetration for MiSight and other silicone hydrogel franchises.

Industry Context

StockSavvy.ai notes that while Cooper Companies maintains a strong competitive position in the contact lens market alongside giants like Alcon and Johnson & Johnson, the significant litigation charge highlights the high-risk nature of the specialized medical device and fertility sectors. The 8% revenue growth suggests that underlying market demand remains healthy despite these legal headwinds.

Comparison to Industry Standards

• CooperVision's 30% operating margin in its core segment is highly competitive within the medical device industry.
• The 8% revenue growth aligns with or slightly exceeds the growth rates of major competitors in the vision care space.
• The $324.1 million gross litigation accrual is a substantial outlier compared to typical quarterly operating expenses for mid-to-large cap medical technology firms.

Legal Proceedings

• Dispute with HM Revenue & Customs (HMRC) regarding payroll tax withholding from the 2014 Sauflon acquisition; potential liability up to £71.7 million.
• Over 140 lawsuits and 1,500 claimants related to the voluntary recall of LifeGlobal embryo culture media, with a recorded net accrual of $271.6 million.

Stakeholder Impact

• Shareholders face a significant quarterly loss and potential share price volatility due to legal liabilities.
• Customers and patients are impacted by the voluntary recall of embryo culture media.
• Creditors see a decrease in working capital but benefit from extended debt maturities and a large available credit facility.

Next Steps

• Appeal the UK First-tier Tribunal's decision regarding the Sauflon payroll tax dispute.
• Resolve outstanding claims and lawsuits related to the LifeGlobal embryo culture media recall.
• Continue the expansion of manufacturing and R&D capacity with $140.2 million in new lease commitments.
• Execute the remaining $860.8 million authorized under the share repurchase program.

Key Dates

Recommendation

The underlying business segments are performing well with 8% revenue growth and strong margins in the vision segment. However, the massive litigation overhang and the potential for further tax liabilities in the UK suggest that investors should wait for more clarity on the final legal costs before increasing positions.

Keywords

Contact Lenses, Fertility, Medical Devices, CooperVision, CooperSurgical, LifeGlobal Recall, Myopia Management, Silicone Hydrogel, Biofinity, MiSight